Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
New England Journal of Medicine2014Vol. 371(4), pp. 326–338
Citations Over TimeTop 1% of 2014 papers
Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, C.E.M. Griffiths, Kim Papp, L. Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen‐Fang Tsai, Norman Wasel, Stephen K. Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, C. Papavassilis
Abstract
Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).
Related Papers
- → Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial(2005)135 cited
- → Efficacy of etanercept in an integrated multistudy database of patients with psoriasis(2006)111 cited
- → Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept(2017)33 cited
- → Clinical and economic impact of etanercept in real-life: A prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER)(2013)8 cited
- → Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study(2022)7 cited